Edition:
United Kingdom

Array Biopharma Inc (ARRY.OQ)

ARRY.OQ on NASDAQ Stock Exchange Global Market

11.49USD
13 Dec 2017
Change (% chg)

$0.67 (+6.19%)
Prev Close
$10.82
Open
$10.92
Day's High
$11.72
Day's Low
$10.90
Volume
1,115,732
Avg. Vol
934,263
52-wk High
$13.38
52-wk Low
$6.74

Select another date:

Mon, Dec 4 2017

BRIEF-Array - In Exchange For $126.06 Million 3.00% Convertible Senior Notes Co Issued 2024 $126.06 Million Notes

* ARRAY BIOPHARMA - ‍ON DEC 1, IN EXCHANGE FOR $126.06 MILLION OF 3.00% CONVERTIBLE SENIOR NOTES DUE 2020 CO ISSUED 2024 NOTES OF $126.06 MILLION

BRIEF-Array Biopharma reports initial results from novel immunotherapy combination at SITC annual meeting

* Array biopharma reports initial results from novel immunotherapy combination at the Society For Immunotherapy Of Cancer (SITC) 32nd annual meeting

BRIEF-ARRAY BIOPHARMA REPORTS Q1 LOSS PER SHARE $0.22

* ARRAY BIOPHARMA REPORTS FINANCIAL RESULTS FOR THE FIRST QUARTER OF FISCAL 2018

BRIEF-Array Biopharma announces proposed public offering of common stock

* Array Biopharma announces proposed public offering of common stock

BRIEF-Array Biopharma announces FDA acceptance for review of Binimetinib and Encorafenib new drug applications for patients with advanced BRAF-mutant melanoma

* Array Biopharma announces FDA acceptance for review of Binimetinib and Encorafenib new drug applications for patients with advanced BRAF-mutant melanoma

BRIEF-Array Biopharma appoints Curtis Oltmans as general counsel

* Array Biopharma appoints Curtis Oltmans as general counsel Source text for Eikon: Further company coverage:

BRIEF-Array Biopharma reports Q4 loss per share $0.17

* Array Biopharma reports financial results for the fourth quarter and full year of fiscal 2017

BRIEF-Amgen and Array BioPharma announce preclinical license and collaboration agreement

* Amgen and Array BioPharma announce preclinical license and collaboration agreement in inflammation

BRIEF-Array Biopharma submits new drug applications to FDA

* Array Biopharma submits new drug applications to FDA for binimetinib and encorafenib in advanced melanoma

Select another date: